BALVERSA® (erdafitinib) for Healthcare Professionals
It’s time to take a different direction THE FIRST AND ONLY treatment indicated specifically for locally advanced or metastatic urothelial carcinoma with susceptible fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations that has progressed after first-line platinum-based chemotherapy1
Set a new direction with your second-line (2L) treatment decision1
1. BALVERSA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.